Health Canada
Symbol of the Government of Canada
About Health Canada

Access to Information Requests Completed - June 2013

The following is a list of Access to Information requests processed by Health Canada. The list is not all-inclusive. The list contains requests completed for which documents have been retrieved or treated. The list is provided in chronological order, by month and year, and by request number. (Requests focusing on personal information or third party proprietary information are not included.)

If you wish to obtain a copy of the records released in response to these requests informally, you may contact the Access to Information and Privacy Division.

AER
Adverse Reaction Report (Adverse Event)
DIN
Drug Identification Number
NPN
Natural Product Number
 
For the month of June 2013
Request # Summary of Requests Status of Completed Request Number of Pages Disclosed
A-2010-00559 All documents pertaining to Health Canada's assessment of benzylpiperazine (BZP), 1-(3-trifluoromethyl-phenyl) piperazine (TEMPP) and six other derivatives of benzylpiperazine and phenylpiperazine. Disclosed in part 495
A-2010-00626 All data related to incident rates of Fetal Alcohol Spectrum Disorder (FASD) on Manitoba reserves. Disclosed in part 611
A-2011-00382 All documents prepared for the Fifth Meeting of the Conference of the Parties to the Rotterdam Convention (COP-5) related to the inclusion of Chrysotile Asbestos in Annex III to the Rotterdam Convention. (May 2011 to Jul 5, 2011). Disclosed in part 333
A-2011-00614 All documents of health claims made concerning Oat Products and Blood Cholesterol and Heart Health relating to submissions made of PepsiCo Canada ULC, PepsiCo Foods Canada, or Quaker requesting approval for the use of disease risk reduction claims related to products containing oats; and any complaints, investigations or reports concerning the use of disease risk reduction claims in advertising relating to products containing oats made by the aforementioned companies. (Jan 1, 2009 to Aug 15, 2011). Disclosed in part 99
A-2011-01256 All documents regarding the proposed sodium-reduction plan/report developed by the Sodium Working Group. (Jun 1, 2011 to Dec 22, 2011). Disclosed in part 4,459
A-2011-01433 Information regarding the product Genestra Brands Tim, NPN 00728926 by Seroyal International. Disclosed in part 99
A-2011-01469 Information regarding the NPN 80004926. Disclosed in part 84
A-2011-01474 Information regarding the NPN 80017296. Disclosed in part 20
A-2011-01475 Information regarding the NPN 80017302. Disclosed in part 16
A-2011-01477 Information regarding the NPN 80017660. Disclosed in part 13
A-2011-01478 Information regarding the NPN 80017662. Disclosed in part 19
A-2011-01479 Information regarding the NPN 80022409. Disclosed in part 35
A-2011-01480 Information regarding the NPN 80024926. Disclosed in part 18
A-2011-01481 Information regarding the NPN 80025034. Disclosed in part 22
A-2011-01485 All documents related to Health Canada's investigation of a complaint in 2008-2009 about fecal contamination of the consumer product Cold-FX. Disclosed in part 329
A-2011-01546 All Health Canada documents on the Supreme Court of Canada's ruling (specifically the review of the ruling) related to the Assisted Human Reproduction Act and Assisted Human Reproduction Canada. (Mar 1, 2011 to Mar 1, 2012). Disclosed in part 396
A-2011-01641 Medical Device Mandatory Problem Reports. For the following Health Canada incident identification numbers: 67073, 64746, 62470, 61088, 60646, 59829, 59820, 59601 and 57540. Disclosed in part 48
A-2012-00314 All documents prepared or created by the Minister of Health or the Minister of Health's office following the analysis and report showing that 10% of federal buildings contain more than a 10% level of radon, which is not in compliance with the standard. Disclosed in part 157
A-2012-01072 Final or most recent version of Safety Code 6 and rationale provided to the Royal Society of Canada related to Health Canada's Internal Review of Science on the biological and health effects of electromagnetic fields completed in 2012. Disclosed in part 120
A-2012-01091 AERs. Report numbers: 000430816 and 000443172. Disclosed in part 6
A-2012-01155 All written correspondence relative to the results of the assessment of the health risks associated with exposure to trans fats and sodium, including the interim results of these assessments and the recommendations regarding measures to be implemented. (Jan. 1, 2012 to Dec. 13, 2012). Disclosed in part 1
A-2012-01240 Documents that contain the contact information and email address for all businesses that hold a Medical Device Establishment Licence for 2012. Disclosed in part 60
A-2012-01316 Information regarding the medical devices Beautical 5 and Beautical 2 Dermal Implants, Device Identifier numbers BC5/1.0 and BC2/1.0 by Rofil Medical Nederland BV. Disclosed in part 219
A-2012-01367 Information regarding the sales of the following 5 specific herbicide active ingredients:
  • Chlorothalonil (2,4,5,6-tetrachloroisophthalonitrile)
  • 2,4D (2,4-Dichlorophenoxyacetic acid)
  • MCPP (methylchlorophenoxypropionic acid)
  • MCPA (2-methyl-4-chlorophenoxyacetic acid)
  • Atrazine (2-chloro-4-(ethylamino)-6-(isopropylamino)-s-triazine)
Disclosed in part 52
A-2012-01392 Information regarding the product Ultram, DIN 02349469 by Janssen Inc. Disclosed in part 104
A-2012-01417 Documents relating to any consideration given by the Food-NHP (Natural Health Product) Classification Committee to the reclassification of 'vitaminwater' products from natural health products to foods. Disclosed in part 7
A-2012-01439 Manuals, or other resources prepared by the department to offer assistance to medical practitioners and other healthcare professionals who are asked to provide medical advice and care to Indian Residential School aboriginal student survivors and the intergenerational impact on their families in the course of their professional work. Disclosed in part 236
A-2012-01488 All documents regarding a meeting held July 7, 2009 on the topic of Adverse Health Effects and Wind Turbines. Disclosed in part 175
A-2012-01513 Information regarding the medical devices Eight-Plate Guided Growth System, License number 70083 by Orthofix Inc. Disclosed in part 226
A-2012-01534 All documents related to the reclassification of methylendioxymethamphetamine (MDMA) from a schedule III substance to a schedule I substance. Disclosed in part 565
A-2012-01557 AERs for the product Diazepam. Report numbers: 000014757, 000026095, 000026989, 000037709, 000070579, 000074250, 000082406, 0000108346, 000115698 and 000224003. Disclosed in part 104
A-2012-01579 All documents regarding the current proposed regulatory changes to the Hazardous Products (Matches) Regulations for safety matches. All disclosed 52
A-2012-01595 All electronic correspondence regarding the development of answers to the questions posted by employees on the Tripartite Employee Corner Questions and Answers page. Disclosed in part 625
A-2012-01657 AERs for the product Epival. Report numbers: 000440835 and 000443492. Disclosed in part 9
A-2012-01703 All information regarding Finasteride. (Jan 1, 2010 to Sep 30, 2012). Disclosed in part 200
A-2012-01705 AERs. Report numbers: 000463957, 000454055, 000456374, 000452455, 000461389, 000382569, 000439137 and 000426721. Disclosed in part 24
A-2012-01721 Information regarding the product Probiostick, NPN 80021343. Disclosed in part 113
A-2012-01722 Information regarding the product Probiokid, NPN 80019993. Disclosed in part 54
A-2012-01723 Information regarding the product Protecflor, NPN 80021342. Disclosed in part 56
A-2012-01725 Information regarding the product Saccharomyces Boulardii, NPN 80038395. Disclosed in part 26
A-2012-01730 Information regarding the product Colgate Optic White Dual Action, NPN 80040148. Disclosed in part 40
A-2012-01764 List of all English and French titles of files, programs, sub-programs, activities, sub-activities and projects classified under Joint Venture and Liaison activities in the Health Canada Function-Based Classification System / Norme de classification fonctionnelle de Santé Canada. All disclosed 2
A-2013-00032 Documents pertaining to the production of the following video, on Wi-Fi, in which Dr. Krewski provides his opinion. Wi-Fi Health Canada Disclosed in part 210
A-2013-00088 The overall number of production sites and licenses to produce cannabis (marihuana) that have been issued under the Marihuana Medical Access Program to recipients within the District of Maple Ridge, British Columbia. (Jan 1, 2011 to May 8, 2013). All disclosed 1
A-2013-00121 Documents regarding the SPF (Sun Protection Factor) obtained in or developed by a sunbed is between 2 and 4 SPF. Disclosed in part 385
A-2013-00123 The overall number of production sites and licenses to produce cannabis (marihuana) that have been issued under the Marihuana Medical Access Program to recipients within the City of Pitt Meadows, British Columbia. (Jan 1, 2011 to May 8, 2013). All disclosed 1
A-2013-00149 Information pertaining to losses and thefts reports for the product OxyNeo. (Sep 1, 2012 to Dec 31, 2012). All disclosed 5
A-2013-00150 Information pertaining to losses and thefts reports for the product Hydromorph Contin. (Sep 1, 2012 to Dec 31, 2012). All disclosed 7
A-2013-00151 Information pertaining to losses and thefts reports for the product OxyContin. (Sep 1, 2012 to Dec 31, 2012). All disclosed 2
A-2013-00152 Information pertaining to losses and thefts reports for the product Dilaudid. (Sep 1, 2012 to Dec 31, 2012). All disclosed 4
A-2013-00197 Documents explaining the rationale for not reporting information data/privacy breaches to the Office of the Privacy Commissioner as required under section 6 of the Treasury Board Guidelines on Privacy Breaches. Relates to all unreported privacy breaches identified in the House of Commons order paper question 8555-411-1217. All disclosed 16
A-2013-00200 AERs for the product Cialis. Report numbers: 00468271 and 00490967. Disclosed in part 3
A-2013-00201 AER for the product Effient. Report number: 000477654. Disclosed in part 1
A-2013-00204 AERs for the product Forteo. Report numbers: 000474926, 000479057 and 000479061. Disclosed in part 7
A-2013-00205 AER for the product Zyprexa. Report number: 000478969. Disclosed in part 1
A-2013-00207 AER for the product Humalog Mix 25. Report number: 000473676. Disclosed in part 1
A-2013-00213 Documents on the results of the cross-Canada radon survey conducted between 2010 and 2011. All disclosed 710
A-2013-00216 A copy of the new code of conduct and/or ethics for Health Canada employees. All disclosed 50
A-2013-00217 All laboratory test results for Health Canada's testing of 7 samples of the consumer product Cold FX following a complaint of faecal contamination of the product in 2008. All disclosed 37
A-2013-00218 A listing of the Access to Information requests submitted to Health Canada during the period of April 2013. Disclosed in part 10
A-2013-00223 Documents regarding the overtime pay between (1997- 2011) for the all employees reporting to the Director of Operational Services and Division and the Manager of Applications Management and Maintenance. Disclosed in part 30
A-2013-00225 Copy of the most recent report (as of May 15, 2013) that captures prescription drug use in First Nations Canadians communities. All disclosed 111
A-2013-00247 Information on Edwards Lifesciences investigational transcatheter prosthetic mitral valve replacement used in compassionate cases. No records exist 0
A-2013-00253 AER for the product Androgel AR. Report number: 000470966. Disclosed in part 1
A-2013-00255 AER for the product Mavik AR. Report number: 000475126. Disclosed in part 1
A-2013-00257 A listing of the Access to Information requests submitted to Health Canada. (Jan 1, 2013 to Jan 31, 2013). Disclosed in part 5
A-2013-00258 A listing of the Access to Information requests submitted to Health Canada. (Feb 1, 2013 to Feb 28, 2013). Disclosed in part 11
A-2013-00277 All correspondence between Crop Life Canada & the Minister of Health and/or her exempt staff in 2011 and 2012. No records exist 0
A-2013-00285 Information regarding the product Symbicort by AstraZeneca Canada Inc. Disclosed in part 2,401
A-2013-00297 All documents concerning the economic, public finance or health implications of the current or hypothetical applications to food of: Goods and services tax/harmonized sales tax (GST/HST), provincial Sales Tax, or sugar sweetened beverage taxes. (Jun 4, 2005 to Jun 4, 2013) No records exist 0